Hospital San Cecilio
Hospital San Cecilio
Yebra G.,CIBER ISCIII |
de Mulder M.,CIBER ISCIII |
Martin L.,CIBER ISCIII |
Rodriguez C.,Centro Sanitario Sandoval |
And 6 more authors.
Antiviral Research | Year: 2011
Background: HIV-1 group M is classified into 9 subtypes and recombinants (CRFs/URFs). Variants other than subtype B (non-B) cause 90% of infections worldwide. HIV is often subtyped using automated tools instead of the gold-standard phylogenetic analysis. We evaluated the reliability of subtyping tools vs. phylogeny in a panel of HIV-1 pol sequences from the cohort of naïve patients of the HIV/AIDS Spanish Research Network (CoRIS). Methods: HIV-1 subtyping was performed using seven automated subtyping tools (Stanford, Geno2pheno, Rega, NCBI, EuResist, STAR, TherapyEdge) in HIV-1 pol sequences from 670 CoRIS patients previously subtyped by phylogeny (587 subtype B/83 non-B). Sensitivity with respect to phylogeny was assessed. Results: Most tools correctly classified subtype B, although up to 15% of non-B sequences were wrongly identified as B depending on the tool. For subtype B and CRF02_AG identification, Stanford/NCBI and Geno2pheno/Rega presented the highest/lowest sensitivities, respectively. EuResist and Geno2pheno correctly classified all 13 non-B " pure" subtypes at pol. The efficacy of all subtyping tools dropped clearly when identifying recombinants different from CRF02_AG. Only NCBI05, Rega and STAR identified URF, but with very low sensitivities. NCBI classified the highest number of subtypes B as non-B, and overestimated recombinants, especially when including references of 2009. Conclusions: Automated tools are useful for subtype B identification, although they present serious limitations in classifying variants uncommon in developed regions, especially recombinants. Their sensitivity depends on the prevalence of non-B variants in the population, and decreases drastically when the frequency of recombinants increases. Furthermore, HIV-1 variant distribution differs according to the tool used. © 2010 Elsevier B.V.
Prevalence and clinical characteristics of chronic venous disease in patients seen in primary care in Spain: Results of the international study Vein Consult Program [Prevalencia y características clínicas de la enfermedad venosa crónica en pacientes atendidos en Atención Primaria en España: Resultados del estudio internacional Vein Consult Program]
Escudero Rodriguez J.-R.,Hospital Of La Santa Creu I Sant Pau |
Fernandez Quesada F.,Hospital San Cecilio |
Bellmunt Montoya S.,Hospital Of La Santa Creu I Sant Pau
Cirugia Espanola | Year: 2014
Introduction: The aim of this study was to evaluate the prevalence, clinical characteristics and management of chronic venous disease (CVD) in patients seen at primary care clinics. Patients and methods: This cross-sectional study was carried-out in Spain by 999 primary care physicians. They recruited 20 consecutive patients who were attending their clinics for any reason except for a medical emergency. The following Information was collected: demographic data, CVD risk factors, physical examination, clinical characteristics of the CVD and how it was managed. Results: 19,800 patients were included, predominantly women (63%), with a mean age of 53.7 ± 20 years. The prevalence of CVD (CEAP categories C1 to C6) was 48.5% (95% CI, 47.8 to 49.2), significantly higher in women (58.5%; 95% CI, 57.6 to 59.4) than in men (32.1%; 95% CI, 31.0 to 33.1). The greater the age the higher the prevalence and the more advanced the CVD. Ninety-nine percent of the patients required some form of treatment, with a greater proportion among women (72% vs. 39%, P<.0001). Sclerotherapy, endothermal ablation or surgery was required by 4% of the patients. Referral to the specialist was considered for 7% of the patients. Conclusion: Chronic venous disease is highly prevalent among patients seen at primary care clinics in Spain, especially in women and elderly patients. Referral to a specialist and/or the use of the more invasive treatment procedures is uncommon. © 2013 AEC.
Darba J.,University of Barcelona |
Restovic G.,Health Economics and Outcomes Research |
Kaskens L.,Health Economics and Outcomes Research |
Balbona M.A.,Hospital Universitario La Paz |
And 6 more authors.
Osteoporosis International | Year: 2011
Summary: In Spain, various treatments are available to prevent osteoporotic fractures. A discrete choice experiment (DCE) was used to investigate the importance of different treatment aspects and its influence on patients' preferences. All attributes included as type and place of drug administration as well as costs showed to be significant predictors of choice. Spanish osteoporosis patients have well-defined preferences and accept trade-offs among attributes. Introduction This study was designed to identify patient preferences for different aspects of osteoporosis treatments in Spain. Methods Main attributes of severe osteoporosis treatments were determined by literature review and consultations with nurses. The discrete choice experiment included three attributes: type of drug administration, place of administration, plus a cost attribute in order to estimate willingness to pay for improvements in attribute levels. A pilot study with 50 patients was performed to identify the areas of misunderstanding. One hundred sixty-six patients with a diagnosis of osteoporosis and severe osteoporosis were presented with pairs of hypothetical treatment profiles with different type of administration levels, places of administration and costs. Questions to collect socio-demographic and disease-related treatment data were also included. Data were analysed using a random effects probit model. Results All attributes had the expected polarity and were significant predictors of choice. Patients were willing to pay 183 €/month to have a subcutaneous injection once per day rather than an intravenous injection once per year. Patients with osteoporosis were willing to pay 121 €/month to have medical support when administering the drug treatment at home rather than being admitted several hours to a hospital for drug administration. Conclusion Spanish osteoporosis patients have well-defined preferences among treatment attributes and are willing to accept trade-offs among attributes. Participants indicated that they are willing to accept self medication with medical support rather than being hospitalised for several hours. The perspective of the patients should be taken into account when making treatment decisions. © International Osteoporosis Foundation and National Osteoporosis Foundation 2010.
Diaz-Llopis M.,University of Valencia |
Diaz-Llopis M.,Hospital Clinico San Carlos |
Salom D.,University of Valencia |
Garcia-De-Vicuna C.,Hospital Sant Joan Of Deu |
And 14 more authors.
Ophthalmology | Year: 2012
Objective: To evaluate adalimumab therapy in refractory uveitis. Design: Prospective case series. Participants: A total of 131 patients with refractory uveitis and intolerance or failure to respond to prednisone and at least 1 other systemic immunosuppressive drug participated. Intervention: Patients received a 40 mg adalimumab subcutaneous injection every other week for 6 months. The associated immunosuppressants were tapered after administering 3 adalimumab injections (week 6). Main Outcome Measures: Degree of anterior and posterior chamber inflammation (Standardization of Uveitis Nomenclature Working Group criteria), immunosuppression load (as defined by Nussenblatt et al), visual acuity (logarithm of the minimal angle of resolution [logMAR]), and macular thickness (optical coherence tomography). Results: There were 61 men and 70 women (mean age, 27.3 years). The most common causes were juvenile idiopathic arthritis in 39 patients, pars planitis in 16 patients, and Behçet's disease in 13 patients. Twenty-seven patients had uveitis of idiopathic origin. Inflammation in the anterior chamber was present in 82% of patients and in the vitreous cavity in 59% of patients. Anterior chamber inflammation and vitreous inflammation decreased significantly (P < 0.001) from a mean of 1.51 and 1.03 at baseline to 0.25 and 0.14, respectively, at 6 months. Macular thickness was 296 (102) μ at baseline versus 240 (36) μ at the 6-month visit (P < 0.001). Visual acuity improved by -0.3 logMAR in 32 of 150 eyes (21.3%) and worsened by +0.3 logMAR (-15 letters) in 5 eyes (3.3%). The dose of corticosteroids also decreased from 0.74 (3.50) to 0.20 (0.57) mg/kg/day (P < 0.001). Cystoid macular edema, which was present in 40 eyes at baseline, showed complete resolution in 28 eyes at 6 months. The mean suppression load decreased significantly (8.81 [5.05] vs 5.40 [4.43]; P < 0.001). Six months after the initiation of the study, 111 patients (85%) were able to reduce at least 50% of their baseline immunosuppression load. Only 9 patients (6.9%) had severe relapses during the 6 months of follow-up. Conclusions: Adalimumab seems to be well tolerated and helpful in decreasing inflammatory activity in refractory uveitis and may reduce steroid requirement. Further controlled studies of adalimumab for uveitis are warranted. Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article. © 2012 American Academy of Ophthalmology.
Croca S.,University College London |
Sangle S.,King's College London |
Vital E.M.,University of Leeds |
Catapano F.,University of Cambridge |
And 11 more authors.
Autoimmunity Reviews | Year: 2012
Objective: To present a pooled analysis of the efficacy of rituximab from European cohorts diagnosed with biopsy-proven lupus nephropathy (LN) who were treated with rituximab. Methods: Consecutive patients with biopsy-proven LN treated with rituximab in European reference centers were included. Complete response (CR) was defined as normal serum creatinine with inactive urinary sediment and 24-hour urinary albumin < 0.5. g, and partial response (PR) as a > 50% improvement in all renal parameters that were abnormal at baseline, with no deterioration in any parameter. Results: 164 patients were included (145 women and 19 men, with a mean age of 32.3. years). Rituximab was administered in combination with corticosteroids (162 patients, 99%) and immunosuppressive agents in 124 (76%) patients (cyclophosphamide in 58 and mycophenolate in 55). At 6- and 12-months, respectively, response rates were 27% and 30% for CR, 40% and 37% for PR and 33% for no response. Significant improvement in 24-h proteinuria (4.41 g. baseline vs 1.31 g post-therapy, p = 0.006), serum albumin (28.55 g baseline to 36.46 g post-therapy, p < 0.001) and protein/creatinine ratio (from 421.94 g/mmol baseline to 234.98 post-therapy, p < 0.001) at 12 months was observed. A better response (CR + PR) was found in patients with type III LN in comparison with those with type IV and type V (p = 0.007 and 0.03, respectively). Nephrotic syndrome and renal failure at the time of rituximab administration predicted a worse response (no achievement of CR at 12. months) (p < 0.001 and p = 0.024, respectively). Conclusion: Rituximab is currently being used to treat refractory systemic autoimmune diseases. Rituximab may be an effective option for patients with lupus nephritis, especially those refractory to standard treatment or who experience a new flare after intensive immunosuppressive treatment. © 2011 Elsevier B.V.
Cantarero-Villanueva I.,University of Granada |
Fernandez-Lao C.,University of Granada |
Fernandez-de-las-Penas C.,Rey Juan Carlos University |
Lopez-Barajas I.B.,Hospital San Cecilio |
And 3 more authors.
Pain Medicine (United States) | Year: 2012
Objective. To evaluate the effects of an 8-week water physical therapy program on cervical and shoulder pain, pressure sensitivity, and the presence of trigger points (TrPs) in breast cancer survivors. Design. Randomized, controlled trial. Setting. To date, no study has investigated effects of water therapy in breast cancer. Patients. Sixty-six breast cancer survivors were randomly assigned into two groups: WATER group, who received a water exercise program or CONTROL group who received the usual care treatment for breast cancer. Interventions. The WATER therapy program consisted of 24 sessions (3 times/week over 8 weeks) of low-intensity exercises in a warm pool (32°C). Each session included 10-minute warm-up period; 35 minutes of aerobic, low-intensity endurance, and core stability training; and a 15-minute cool-down period (stretching and relaxation). Outcomes. Neck and shoulder pain (visual analog scale, 0-100mm), pressure pain thresholds (PPTs) over C5-C6 zygapophyseal joints, deltoid muscles, second metacarpal, and tibialis anterior muscles, and the presence of TrPs in cervical-shoulder muscles were assessed at baseline and after the 8-week program by an assessor blinded to treatment allocation. Results. The WATER group demonstrated a between-group improvement for neck pain of -31mm (95% confidence interval [CI]-49 to -22, P<0.001; effect size 1.1, 0.81-1.75) and for shoulder-axillary of -19mm (-40 to -04, P=0.046; effect size 0.70, 0.14-1.40). Improvements were also noted for PPT levels over C5-C6 joints (between-group differences, affected side: 27.7kPa, 95% CI 3.9-50.4; unaffected: 18.1kPa, 95% CI 6.1-52.2). No between-group differences for PPT over the remaining points were observed (P>0.05). Finally, patients in the WATER program showed a greater reduction of active TrPs as compared with the CONTROL group (P<0.05). Conclusions. An 8-week water therapy program was effective for improving neck and shoulder/axillary pain, and reducing the presence of TrPs in breast cancer survivors as compared with usual care; however, no significant changes in widespread pressure pain hyperalgesia were found. © 2012 American Academy of Pain Medicine.
Olivares Romero J.,Hospital Torrecardenas |
Arjona Padillo A.,Hospital Torrecardenas |
Barrero Hernandez F.J.,Hospital San Cecilio |
Martin Gonzalez M.,Hospital Torrecardenas |
Gil Extremera B.,University of Granada
European Journal of Neurology | Year: 2013
Background and purpose: Drug-induced parkinsonism usually resolves after discontinuation of the causative agent. However, it persists in some patients, who actually have subclinical neurodegenerative parkinsonism. Identification of this condition is important because these patients could benefit from therapeutic measures. The objective of this study was to prove whether transcranial sonography, a technique used in the diagnosis of neurodegenerative parkinsonism, can be used for the said identification. Methods: In this prospective study, patients with drug-induced parkinsonism were followed for at least 6 months after discontinuation of the causative drug and performance of blinded transcranial sonography. Patients were categorized as having iatrogenic parkinsonism if the clinical presentation had resolved or subclinical drug-exacerbated parkinsonism if it persisted. Once the patient was classified into one of the two groups, an expert assessed the transcranial sonography findings and their agreement with the clinical diagnosis. Results: Twenty patients composed the group for analysis of results. Assessing hyperechogenicity in the substantia nigra >20 mm2 and/or hyperechogenic lentiform nucleus, differences were detected between the iatrogenic parkinsonism and the subclinical drug-exacerbated parkinsonism groups, although they did not reach statistical significance (Fisher's exact test 0.09). Joint assessment of sonographic alterations in both structures had a negative predictive value of 85.7% for diagnosis of drug-induced parkinsonism, with a negative likelihood ratio of 0.3. Conclusions: Although in our study statistically significant differences were not found between the transcranial sonography characteristics of subclinical drug-exacerbated parkinsonism and iatrogenic parkinsonism patients, we believe that transcranial sonography is a valid technique for diagnosis of drug-induced parkinsonism. © 2013 EFNS.
PubMed | Hospital San Cecilio, Hospital Universitario La Paz, Hospital Universitario 12 Of Octubre, Hospital Virgen Of Las Nieves and 2 more.
Type: Journal Article | Journal: Clinical and experimental rheumatology | Year: 2016
To assess the efficacy of tocilizumab (TCZ) in patients with Takayasu arteritis (TA).Multicentre open-label retrospective study.Eight patients (all women) with a mean age of 3416 years, median 36 years (range: 7-57) were assessed. The main clinical features at TCZ therapy onset were: constitutional symptoms (n=4), fever (n=3), headache (n=2), chest pain (n=1), abdominal pain (n=1), mesenteric ischaemia (n=1), myalgia involving the lower limbs (n=1), cerebral vascular insufficiency (n=1), malaise (n=1), upper limb claudication (n=1) and nodular scleritis (n=1). Besides corticosteroids and before TCZ treatment onset, 7 of 8 patients had also received several conventional immunosuppressive and/or biologic agents. Seven patients experienced marked clinical improvement in the first 3 months after the onset of TCZ therapy. After a median follow-up of 15.5 [interquartile range-IQR: 12-24] months, 7 patients were asymptomatic. The median C-reactive protein decreased from 3.09 [IQR: 0.5-12] to 0.15 [IQR: 0.1-0.5] mg/dL (p=0.018), and median erythrocyte sedimentation rate from 40 [IQ range: 28-72] to 3 [IQR: 2-5] mm/1st hour (p=0.012). The median dose of prednisone was also tapered from 42.5 [IQR: 25-50] to 2.5 [IQR: 0-7.5] mg/day (p=0.011). However, TCZ had to be discontinued in 1 patient because she developed a systemic lupus erythematosus, and in another patient due to inefficiency. TCZ dose was reduced in a patient because of mild thrombocytopenia.TCZ appears to be effective in the management of patients with TA, in particular in patients refractory to corticosteroids and/or conventional immunosuppressive drugs.
Codoner F.M.,Institute Of Recerca Of La Sida Irsicaixa Hivacat |
Codoner F.M.,Lifesequencing S.L. |
Pou C.,Institute Of Recerca Of La Sida Irsicaixa Hivacat |
Thielen A.,Max Planck Institute for Informatics |
And 9 more authors.
PLoS ONE | Year: 2011
Objective: To explore the potential of deep HIV-1 sequencing for adding clinically relevant information relative to viral population sequencing in heavily pre-treated HIV-1-infected subjects. Methods: In a proof-of-concept study, deep sequencing was compared to population sequencing in HIV-1-infected individuals with previous triple-class virological failure who also developed virologic failure to deep salvage therapy including, at least, darunavir, tipranavir, etravirine or raltegravir. Viral susceptibility was inferred before salvage therapy initiation and at virological failure using deep and population sequencing genotypes interpreted with the HIVdb, Rega and ANRS algorithms. The threshold level for mutant detection with deep sequencing was 1%. Results: 7 subjects with previous exposure to a median of 15 antiretrovirals during a median of 13 years were included. Deep salvage therapy included darunavir, tipranavir, etravirine or raltegravir in 4, 2, 2 and 5 subjects, respectively. Self-reported treatment adherence was adequate in 4 and partial in 2; one individual underwent treatment interruption during follow-up. Deep sequencing detected all mutations found by population sequencing and identified additional resistance mutations in all but one individual, predominantly after virological failure to deep salvage therapy. Additional genotypic information led to consistent decreases in predicted susceptibility to etravirine, efavirenz, nucleoside reverse transcriptase inhibitors and indinavir in 2, 1, 2 and 1 subject, respectively. Deep sequencing data did not consistently modify the susceptibility predictions achieved with population sequencing for darunavir, tipranavir or raltegravir. Conclusions: In this subset of heavily pre-treated individuals, deep sequencing improved the assessment of genotypic resistance to etravirine, but did not consistently provide additional information on darunavir, tipranavir or raltegravir susceptibility. These data may inform the design of future studies addressing the clinical value of minority drug-resistant variants in treatment-experienced subjects. © 2011 Codoñer et al.
Labarga P.,Hospital Carlos III |
Soriano V.,Hospital Carlos III |
Caruz A.,University of Jaén |
Poveda E.,Hospital Carlos III |
And 8 more authors.
AIDS | Year: 2011
BACKGROUND: IL28B polymorphisms influence both the rate of spontaneous hepatitis C virus (HCV) clearance and response to interferon α (IFNα)-based therapy. This observation has been reproduced in HIV-co-infected individuals. Controversy exists about the impact of IL28B alleles on HCV load. METHODS: CoRIS is a nationwide, open cohort of newly diagnosed HIV-1 adults in Spain. In the subset of HCV-co-infected individuals, the relationship between plasma HCV-RNA and IL28B (rs12979860) genotypes was evaluated. RESULTS: A total of 4670 HIV-1-infected patients had been included in CoRIS up to June 2010. All were naive for IFNα. HCV antibodies were reactive in 895 (19%). Of them, 289 specimens were available and tested positive for plasma HCV-RNA, with median values of 959 900 IU/ml. The rs12979860 genotype distribution in HCV viremic patients was CC 45%, CT 42.2% and TT 12.8%. The median plasma HCV-RNA according to IL28B genotypes was: CC 1 385 000, CT 848 939 and TT 251 189 IU/ml (P = 0.006). The percentage of patients with HCV-RNA more than 600 000 IU/ml was: CC 67.7%, CT 56.6% and TT 35.1% (P = 0.001). In multivariate analysis, IL28B CC/CT genotypes, infection with HCV genotypes 1/4 and prior intravenous drug users were independent predictors of HCV-RNA more than 600 000 IU/ml. CONCLUSION: HIV/HCV-co-infected patients with the C allele (CC/CT) at rs12979860 show significantly higher plasma HCV-RNA load than TT carriers. Notably, plasma HCV-RNA levels associated with poorer response to IFNα-based therapy are significantly more frequent in CC/CT than TT carriers. Hypothetically, patients harboring the rs12979860 allele C could display a lower activity of endogenous IFNα, allowing higher HCV replication while keeping an enhanced susceptibility to exogenous IFNα therapy. © 2011 Lippincott Williams & Wilkins, Inc.